Sleep impairment and insomnia in sickle cell disease: A retrospective chart review of clinical and psychological indicators

2015 ◽  
Vol 27 (8) ◽  
pp. 441-449 ◽  
Author(s):  
Valerie Mann-Jiles ◽  
Kathrynn Thompson ◽  
Joanne Lester
Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 1017-1017
Author(s):  
Marwah W. Farooqui ◽  
Santosh Saraf ◽  
Victor R. Gordeuk ◽  
Kimberly Czech ◽  
Eunice John ◽  
...  

Abstract Abstract 1017 In sickle cell disease, patients are predisposed to renal dysfunction and eventual renal failure as they reach adulthood. Many advances have been made within the field of sickle cell anemia, yet to this day sickle cell nephropathy remains an important cause of mortality in adult patients. Previous studies have determined that proteinuria and hematuria are two useful markers of sickle cell nephropathy. Currently, the best marker for detecting early renal dysfunction is proteinuria on urine dipstick due to its ease of use and efficiency. Our goal in this study is to determine the age at which the first signs of renal dysfunction appear. Pediatric patients with sickle cell disease were selected for a retrospective chart review to determine age of onset for renal abnormalities. The sickle cell pediatric roster was used from the Children's Hospital University of Illinois to study a total of 175 patients within the age range of 0–31 years. Urinalysis was captured at patient's baseline when available and possible risk factors for glomerular dysfunction were studied. Factors such as urine protein and blood on dipstick were recorded and proteinuria was further quantified by using the urine protein to creatinine ratio. Blood on dipstick was further analyzed by red blood cells on microscopic urinalysis. Patients with positive urine for blood on dipstick with <5 RBCs on microscopic UA were marked as patients with hemoglobinuria. Other factors such as sickle cell hemoglobin type, LDH, reticulocyte count, HbF, and hydroxyurea treatment were also recorded to look for correlation with predictors of early renal dysfunction. The Fisher's exact test was used to compute the (two-tailed) probability. Urinalysis results were available for 141 of the 175 pediatric patients from the sickle cell roster. From the 141 patients that were studied 65% of the patients had urinalysis done at baseline, the other 35% had UA when acutely ill. The mean overall age was 9.9 years and a total of 25 of the 141 (17.7%) patients were observed to have proteinuria on dipstick. In the proteinuria group, 64% of the UA were obtained at baseline and the other 36% were during a sick visit. The majority (66%) of these ‘sick’ patients were febrile under the age of 7. Obtaining a UA during an acute illness could skew our results since pediatric patients who are acutely ill may have transient proteinuria but none at baseline. In our pediatric sickle cell population, about 14% had hemoglobinuria. Analysis of only baseline UA showed that no patients under the age of 5 at baseline had proteinuria and there is a strong correlation between age and proteinuria (R2 = 0.81, p<0.02). Similarly there is a correlation between age and hemoglobinuria (R2 = 0.57). Hemoglobinuria is occasionally observed in 11.4% of children <5 years of age, and at 12.9% in the teenage group. A significant increase in incidence of hemoglobinuria is noted in the young adults (40%). Of the 16 patients with hemoglobinuria only 8 had concurrent proteinuria. A larger sample size is needed to determine whether proteinuria and hemoglobinuria are independent versus correlated markers of early renal dysfunction. Preliminary analyses of baseline UA found no correlations between proteinuria and Hb level, LDH, reticulocytes, serum creatinine, or creatinine clearance. From this retrospective chart review in this pediatric sickle cell disease population, it can be deduced that proteinuria becomes a concern in sickle patients in the adolescent years while hemoglobinuria appears in late teen to young adult years. It can be concluded that the first clinical signs of renal dysfunction which lead to nephropathy in sickle patients are more frequently seen in adolescent to late teen years and this is likely the marks the beginning of the deterioration of kidney function. Further studies are needed for multivariate analysis of other markers (GFR, Cr, Cr Clearance) of nephropathy and to improve early detection of renal dysfunction by conducting longitudinal studies. Our goal is to improve our current practice by routine screening in sickle patients to preserve renal function and improve the morbidity and mortality related to sickle cell nephropathy in the aging patient. Disclosures: No relevant conflicts of interest to declare.


Blood ◽  
2019 ◽  
Vol 134 (Supplement_1) ◽  
pp. 4856-4856
Author(s):  
Chibuzo Ilonze ◽  
Michael P Anderson ◽  
Alexander Stubblefield ◽  
Janna M. Journeycake ◽  
Arpan Sinha

Background: Sickle cell disease (SCD) and its complications are associated with frequent hospital visits and treatment often requires venous access for administration of fluids, medications and blood transfusions. Due to frequent use, peripheral venous access can become difficult over time because of venous scarring. Moreover, certain interventions such as chronic simple or exchange transfusions require reliable venous access for prolonged periods of time. Implantable central venous devices such as ports offer definitive access and mitigate the need for frequent peripheral access attempts. However, existing knowledge on the use of these devices in pediatric patients with SCD is limited. Due to possible increased risks of thrombosis and mechanical occlusion from hypercoagulable state, risk of infectious complications and need for surgical placement, ports are often not used routinely. We review the indications and complications associated with placement of ports in the pediatric cohort of patients with SCD - to better define the scope of port placement in this group. Methods: We performed an IRB-approved, retrospective chart review to assess the indications, complications and risk factors associated with port placement in children and adolescents with SCD at the University of Oklahoma Health Sciences Center (OUHSC). The study period analyzed was 17.5 years from January 1st, 2000 to July 30th, 2018 and included patients from birth to 21 years of age, diagnosed with SCD who had homozygous sickle cell disease (HbSS) or compound heterozygous SCD - either sickle cell-β0-thalassemia, sickle cell-β+-thalassemia or sickle cell-hemoglobin C (HbSC) disease, and had ports in place for more than 7 days. Patients were identified systematically by querying the OUHSC Clinical Data Warehouse using diagnostic codes followed by chart review. Results: Thirty-two patients with SCD and ports were identified during the study period, out of which 31 patients had HbSS and one patient had HbSC disease. The median age at first port insertion was 8 years (range 1-20 years). A total of 63 ports were placed for a total of 99,272 port days with a median port life span of 1340 days. The two main indications for port placement were - either chronic transfusions for which 48 ports were placed for a total of 80,238 port days, or poor venous access (PVA) for which 15 ports were placed for a total of 19,034 port days. Out of the 48 ports placed for chronic transfusions, 6 ports were for transfusions for primary stroke prophylaxis, 22 ports were for transfusions for secondary stroke prophylaxis, 17 ports were for transfusions for recurrent vaso-occlusive episodes (VOE) and 3 ports were for transfusions after multi-organ failure. A total of 54 port complications occurred (malfunction=29, infection=20, thrombosis=3, difficult port access=1, and intractable pain over port site=1). From the data available, more ports were placed in the left subclavian vein (LSV=20) than right subclavian vein (RSV=4) and right internal jugular (RIJ=2), however rate of overall complications were similar between LSV and RSV - 0.57 complications/1,000 catheter days in LSV and 0.58 complications/1,000 catheter days in RSV. The rate of port associated infection, defined as a positive blood culture drawn from the port, was 0.2 per 1,000 port days. A total of 20 infections identified mostly gram-positive organisms (n=15) predominantly Staphylococcus, compared to gram-negatives (n=3), fungus with Candida albicans (n=1) and a rare acid-fast bacilli infection with Mycobacterium mucogenicum (n=1). The rate of thrombosis, identified radiologically using vascular doppler ultrasound, was 0.03 per 1,000 port days. The rate of premature port removal arising from complications was 0.36 per 1,000 port days. Ports placed for chronic transfusions had a lower rate of removal (0.31 per 1,000 port days) compared to ports placed for poor venous access (0.58 per 1,000 port days) with a ratio of 0.54 which approached statistical significance (p=0.09; CI 0.26-1.21). Conclusion: Ports in pediatric patients with SCD are associated with low rates of thrombosis, infection and malfunction. Ports may be a reasonable alternative for vascular access in patients with SCD - especially in patients who require chronic simple or exchange transfusions and have difficult access. Larger prospective studies will be needed to further assess the scope of use of ports in this population. Disclosures No relevant conflicts of interest to declare.


2020 ◽  
Vol 13 (1) ◽  
pp. e2021002
Author(s):  
Manal Alsaif ◽  
Joan Robinson ◽  
Moshtag Abdulbaqi ◽  
Mustafa Aghbari ◽  
Khalid Al Noaim ◽  
...  

Aim: The main aim was to report the prevalence and severity of serious bacterial infections (SBI) in children with sickle cell disease at King Abdulaziz Hospital, Al Ahsa, Saudi Arabia to aid in determining whether outpatient management of such cases is appropriate. Methods: We conducted a retrospective chart review of febrile children less than 14 years of age admitted with sickle cell disease 2005 through 2015. Results: During 320 admissions, 25 children had SBIs (8%) including pneumonia (n=11), osteomyelitis (n=8), bacteremia (n=3, all with Salmonella species) and UTI (n=3). All recovered uneventfully. Conclusion: It appears that in the current era, less than 10% of febrile children with sickle cell disease in our center are diagnosed with a SBI. Over an 11-year period, there were no sequelae or deaths from SBI. Given these excellent outcomes, outpatient ceftriaxone should be considered for febrile well appearing children with sickle cell disease if they have no apparent source and parents are judged to be reliable.


Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 980-980
Author(s):  
I D Greener ◽  
C A Rutledge ◽  
T Abassi ◽  
K Yadav ◽  
A B Desai ◽  
...  

Abstract Introduction Sudden death, ventricular arrhythmias, prolonged QTc on ECG, and myocardial fibrosis have been documented independently in patients with sickle cell disease (SCD). We hypothesized that these electrical abnormalities are associated with myocardial fibrosis, ventricular arrhythmias, and death in SCD. Methods & Results A retrospective chart review of 195 SCD patients seen at the University of Illinois at Chicago was performed evaluating the association of ECG intervals with documented mortality and/or ventricular tachycardia (VT). Only ECGs demonstrating normal sinus rhythm and heart rates < 100 were included. Significant increases in PR (181 + 30 vs 162 + 26 ms, p=0.009), QRS (102 + 24 vs 89 + 11ms, p=0.0002), QTc (456 + 36 vs 441 + 25, p=0.02), and Tp-Te (duration between peak to end of T wave in lead V5, 114 + 46 vs 76 + 23, p=2.11X10-7) intervals were associated with a combined endpoint of all-cause mortality and VT (n=16 compared to n=179 SCD controls) with similar heart rates across both groups (78 + 14 vs. 77 + 11, p=0.72). To elucidate the mechanisms underlying this increased clinical risk in SCD patients, we investigated hearts from a mouse model of SCD. Cardiac electrical stimulation in vivo induced ventricular arrhythmias in 3/4 homozygous (-/-) SCD compared to only 1/5 wild-type (WT) hearts. Interestingly, Tp-Te– an established sudden cardiac death predictor- was significantly prolonged in -/- SCD vs. WT mice (5.6 + 0.29 vs. 4.1 + 0.37 msec ; p<0.05). Furthermore, left ventricular (LV) effective refractory periods (37+ 2.3 vs. 22 + 4.57 ms; p<0.05) and mid-anterior (LV) monophasic action potentials (MAPs) of -/- SCD mice, revealed increased duration compared to WT mice (53 + 2.3 vs. 33 + 6.9 ms; p<0.05). Conclusion In SCD patients, poor clinical outcomes are associated with abnormalities in depolarization and, prominently, repolarization. The SCD mouse exhibited arrhythmia vulnerability associated with repolarization abnormalities (Tp-Te, LV MAPs). The SCD mouse may represent a useful model for deciphering the mechanisms underlying the apparent increased arrhythmia burden in SCD patients. Disclosures: Hillery: Bayer: Consultancy; Biogen Idec: Consultancy.


2016 ◽  
Vol 2016 ◽  
pp. 1-5 ◽  
Author(s):  
Josue Santos ◽  
Sasia Jones ◽  
Daniel Wakefield ◽  
James Grady ◽  
Biree Andemariam

Background.A treatment algorithm for sickle cell disease (SCD) pain in adults presenting to a single emergency department (ED) was developed prioritizing initiation of patient controlled analgesia (PCA) for patients awaiting hospitalization.Objectives.Evaluate the proportion of ED visits in which PCA was started in the ED.Methods.A two-year retrospective chart review of consecutive SCD pain ED visits was undertaken. Data abstracted included PCA initiation, low versus high utilizer status, pain scores, bolus opioid number, treatment times, and length of hospitalization.Results.258 visits resulted in hospitalization. PCA was initiated in 230 (89%) visits of which 157 (68%) were initiated in the ED. Time to PCA initiation was longer when PCA was begun after hospitalization versus in the ED (8.6 versus 4.5 hours,p<0.001). ED PCA initiation was associated with fewer opioid boluses following decision to admit and less time without analgesic treatment (allp<0.05). Mean pain intensity (MPI) reduction did not differ between groups. Among visits where PCA was begun in the ED, low utilizers demonstrated greater MPI reduction than high utilizers (2.8 versus 2.0,p=0.04).Conclusions.ED PCA initiation for SCD-related pain is possible and associated with more timely analgesic delivery.


Blood ◽  
2021 ◽  
Vol 138 (Supplement 1) ◽  
pp. 1886-1886
Author(s):  
Madhav Vissa ◽  
Marsha Treadwell ◽  
Naomi Bardach

Abstract Introduction: People living with sickle cell disease (SCD) are at risk for stroke due to progressive cerebral vasculopathy. The Stroke Prevention Trial in Sickle Cell Anemia (STOP) study showed that transfusion therapy in patients with abnormal cerebral blood flow velocities measured by transcranial doppler (TCD) ultrasound significantly reduced the risk for stroke. Based on the STOP and STOP II studies, the National Heart, Lung and Blood Institute (NHLBI) and American Society of Hematology (ASH) recommend annual TCD screenings for children with HbSS and HbSb0 genotypes from age 2-16. Despite this recommendation, studies show that fewer than half of eligible children with SCD complete annual TCD screening. Recently, Cabana and Treadwell et al. (2020) found high TCD referral and completion rates in a multi-site quality improvement (QI) initiative (85% baseline) using chart review. Another feasible approach to tracking guideline adherence uses administrative claims data which are derived from diagnostic and billing codes from statewide claims. Claims data can be used to assess population estimates for a clinic or a state, for all eligible patients, including those who may not routinely access care. In this study, we use administrative claims to assess TCD completion rates in the same clinics participating in the aforementioned QI initiative. We hypothesized that, population level rates would be lower than those assessed via chart review and that QI strategies may not lead to sustained TCD completion rates. Methods: Between August 2017 to August 2018, a QI initiative within the Pacific Sickle Cell Regional Collaborative (PSCRC) was conducted to improve referral and completion rates of TCD screenings. Site leads participated in a monthly QI learning collaborative, implementing and reporting on Plan-Do-Study-Act (PDSA) cycles, with bimonthly chart review data collection. Medicaid administrative claims from the four states with participating clinics, from 2017, 2018 (to assess baseline and post-QI initiative performance) and 2019 (to assess sustainability), were used to assess rates of TCD completion in the eligible pediatric population, using the specifications of a previously validated quality measure by Reeves et al (2019). Annual TCD completion rates and changes in completion rates over time were assessed for each site and state. Results: Five sites from four states in the PSCRC were included in the analysis. There was large variability in the number of eligible patients in each clinic (13-75) and state (23-588). Based on administrative claims, TCD clinic-level completion rates at baseline ranged from 41.7% to 69.2% at individual clinics. After 12 months of QI participation, TCD completion rates improved at all sites (range 4.6% to 29.2%). The site with the largest change improved TCD completion rate from 41.7% to 70.8% (n=24). All but one site had a decrease in TCD completion rate after completing the QI initiative and in 2019, TCD completion rates were within 10% of baseline completion rates at all sites (range -8.2% to 8.3%). At the statewide level, one state had a sustained improvement in TCD completion (improvement from baseline: 8.8%). In three of the four states providing data, TCD completion rates decreased from baseline (range -0.7% to -12.6%). Discussion: In a regional collaborative, we found improvements in TCD completion in the setting of a QI initiative focused on TCD, which were not sustained in the year after. This suggests the need for a systems-level approach to improvement, leading to feasible sustainability when no longer the focus of a collaborative. In addition, our data show that, when using administrative claims, rates of TCD completion are lower than rates when using chart review data (41.7% to 69.2% vs. 85% by chart review noted in prior publication). Thus, while site-specific medical record review provides insight into the quality of care for patients seen in the clinic, administrative claims data allow for a global understanding of the quality of care for the clinic population at risk, including those who do not attend clinic regularly. This suggests additional potential focus for quality improvement initiatives, such as systems to optimize outreach to patients who may not routinely access care. This type of outreach may best be done by health plans, potentially in partnership with sickle cell specialists, and would be an important tool for improving health for children with SCD. Disclosures Vissa: Global Blood Therapeutics Inc: Research Funding. Treadwell: National Alliance of Sickle Cell Centers: Other: Early Evaluation of the Use of Crizanlizumab in Sickle Cell Disease.


2019 ◽  
Vol 3 (2) ◽  
pp. 63-68 ◽  
Author(s):  
Tian Xia ◽  
Marco A. Zarbin ◽  
Neelakshi Bhagat

Purpose: This article describes the characteristics, management, and etiology of retinal artery occlusions (RAOs) in young patients. Methods: A retrospective chart review of patients <50 years of age with ophthalmic and RAOs was conducted. Data were collected on demographics, clinical presentation, laboratory and imaging evaluation, management, and outcome. Results: Seventeen eyes of 15 patients younger than 50 (mean age, 34±8 years; 71% male, 29% female) with RAOs were identified. AOs included: 8 (47%) central RAOs (CRAOs), 5 (29%) branch RAOs (BRAOs), 3 (18%) ophthalmic AOs (OAOs), and 1 (6%) combined CRAO and vein occlusion (CRAO/CRVO). Logarithm of the minimum angle of resolution visual acuity (VA) at presentation was 2.6±4 (Snellen range 20/15 to no light perception). Systemic diseases in patients with BRAO included Susac disease (n = 1), sickle cell disease (n = 2), patent foramen ovale (PFO) (n = 1), and HIV (n = 1). CRAO was diagnosed in 4 patients after invasive surgery (3 after neurosurgery and 1 after cardiac surgery). Other patients had hypertension (n = 3), hypercoagulability due to uterine cancer (n = 1), and PFO (n = 1). OAOs were noted in 1 patient with Saturday night retinopathy and in 1 with ruptured internal carotid aneurysm at the level of the ophthalmic artery. Two eyes with CRAO were treated with tissue plasminogen activator (1 intraophthalmic artery through catheterization and 1 intravenously) without any change in final VA. In these patients, VA remained poor (VA hand motions – counting fingers) at 6 months or greater follow-up visits. Conclusion: RAO in young patients is uncommon. In this series, one-fourth of occlusions were seen during the perioperative period. A significant number of patients had concurrent uncontrolled hypertension. Other associated systemic findings included PFO, hypercoagulability, sickle cell disease, Susac disease, and HIV.


Blood ◽  
2020 ◽  
Vol 136 (Supplement 1) ◽  
pp. 29-30
Author(s):  
Sharmila Raghunandan ◽  
Derrick L Goubeaux ◽  
Christine R Hollenkamp ◽  
Rae M Blaylark ◽  
Stephen C Nelson

Background: Acute splenic sequestration is a potentially life-threatening complication in patients with sickle cell disease. It is the second leading cause of death in young children with hemoglobin SS/Sβ0 thalassemia (SCD). The incidence approaches 35% during the first two years of life in SCD. Although splenic sequestration can occur in patients with any sickle phenotype, patients with SCD tend to be significantly younger when compared to patients with hemoglobin SC disease. Splenic function may be preserved in children treated with hydroxyurea. We recommend hydroxyurea for all SCD patients diagnosed via newborn screening, with a goal of starting therapy before 12 months of age. With this aggressive approach and potential for maintaining some splenic function, this study evaluates acute splenic sequestration in this young cohort and compares this to institutional and historical controls Methods: We performed a retrospective search of electronic medical records at Children's Minnesota from 1/1/1999 through 12/31/2019 to identify patients with SCD and splenic sequestration. We used a broad array of ICD-9 an ICD-10 codes in order to capture all appropriate patients. Following this initial search, in-depth chart review was performed to identify patients with SCD and confirmed splenic sequestration. Data collected includes age, sex, hydroxyurea use, splenectomy, and hematologic results including hemoglobin F percentage, if available. Student t-tests for independent samples were performed to compare cohorts. This study was granted exemption by our Institutional Review Board. Results: Over this 21 year period, the initial search revealed 151 patients. Of those, 74 had SCD. In-depth chart review found 38 (24M, 14F) of these children were confirmed to have splenic sequestration. Twelve patients started hydroxyurea before 2 years of age at a mean age of 12.6 months, median 11 months (cohort A). Of these, six started hydroxyurea during infancy at a mean and median age of 6.5 months (cohort B). The remaining 26 patients were not on hydroxyurea at the time of splenic sequestration (cohort C). Children in cohorts A and B were significantly older at the time of splenic sequestration compared to patients in cohort C (mean 58 and 45.8 months vs. 14.9 months, p&lt; 0.0001). Conclusions: Children with SCD who start hydroxyurea at a young age may develop splenic sequestration much later in life than previously expected. More study is needed to confirm this finding. It will be important to educate families and healthcare providers about this potential unintended consequence of early hydroxyurea use. Disclosures No relevant conflicts of interest to declare. OffLabel Disclosure: Hydroxyurea use in children with sickle cell disease &lt; 2 years of age


Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 4853-4853
Author(s):  
Andrew S. Freiberg ◽  
Antea C Singleton

Abstract Abstract 4853 Immunization status is often used as an indicator of improved quality of health care and access in pediatric populations. The increased life expectancy in the general pediatric population has largely been attributed to the prevention of infectious disease through immunizations, and this fact is even truer for individuals with sickle cell disease. Adherence to recommended vaccination schedules against encapsulated bacteria in patients with sickle-cell anemia has not been well studied in any population. In order to determine documented compliance rates based on the current recommendations of the Department of Health and Human Services Center for Disease Control Immunization Schedules, a retrospective chart review was performed on 117 patients diagnosed with sickle cell anemia (HbSS) followed at the Penn State Hershey Children's Hospital Regional Pediatric Sickle Cell Center, through the year 2009. Since the vaccinations were given by each patient's primary provider(s), we attempted to obtain documentation of immunizations given by these providers, particularly against encapsulated bacteria. For 35 of the 117 patients, we were unable to obtain any forwarded documentation of any vaccinations. The vaccination schedules of the remaining 82 patients were audited for coverage against encapsulated bacteria. Only 16 of the 82 patients (19.5%) with forwarded documents demonstrated complete documented compliance, defined as having complete coverage against H. influenzae, N. meningitides, and S. pneumococcus. Of the remaining forwarded charts, 63 patients (76.8%) demonstrated some form of partial documented compliance, but four patients (4.9%) did not have documentation of vaccinations against any encapsulated bacteria despite documentation of receiving other vaccinations. Full documented compliance as indicated by forwarded records was most noted in children between the ages of 0–11.9 years (14/16 of patients with complete compliance). The proportion of adolescents without any forwarded documentation was larger than the younger age group; however, this difference did not reach statistical significance (p=0.36). Of the 82 patients whose primary care physicians forwarded documents, significantly more (14 of 34) adolescents (≥12 years of age) than children aged 0–11.9 years (8 of 48) were missing documentation of more than half of their vaccines (p=.014). These results indicate deficient documentation of vaccination coverage against encapsulated organisms, particularly in the adolescent population. To determine the clinical implications of these results, further studies detailing the demographics, socioeconomic status and correlations of such characteristics to morbidity and mortality should be completed. Disclosures: No relevant conflicts of interest to declare.


SAGE Open ◽  
2013 ◽  
Vol 3 (1) ◽  
pp. 215824401348247 ◽  
Author(s):  
Jean L. Raphael ◽  
Xuan G. Tran ◽  
Brigitta U. Mueller ◽  
Angelo P. Giardino

Sign in / Sign up

Export Citation Format

Share Document